Leadership Team

Kerry Blanchard, M.D., Ph.D.

Chief Executive Officer

Dr. Blanchard most recently served as chief scientific officer at a subsidiary of Innovent Biologics, Inc. (HKEX: 1801), from January 2018 to June 2019. He was a senior executive at Eli Lilly (NYSE: LLY) and its subsidiaries from 2000 to December 2017, playing multiple roles including senior vice president of Lilly China and co-chairman of the Lilly Asia Venture investment committee. Dr. Blanchard's scientific and leadership positions in Eli Lilly included Oncology Discovery Biology Research, Lilly Singapore Systems Biology, Discovery operations, and Tailored Therapeutics in Indianapolis.

Dr. Blanchard worked at the Feist-Weiller Cancer Center, Department of Medicine, Louisiana State University Medical Center from 1992 to 1999, including as an associate professor of Louisiana State University, and was a research fellow, a clinical fellow and an instructor in Medicine at the Brigham and Women's Hospital in Boston, Massachusetts, United States, and at Harvard Medical School in Massachusetts, United States from 1985 to 1992.

Dr. Blanchard received his bachelor's degree in chemistry in August 1977, Ph.D. in biochemistry in September 1982 and M.D. in April 1985, each from Indiana University in the United States.

Ian Woo

President and Chief Financial Officer

Prior to joining our Company in June 2018, Mr. Woo served as a managing director in the healthcare advisory team at Lazard Frères & Co. LLC ("LFNY"), a subsidiary of the financial advisory and asset management firm Lazard Ltd (NYSE: LAZ). Mr. Woo joined LFNY in March 2005 and was based in New York until June 2018, other than from January 2012 to June 2016 during which period he worked at Lazard Asia (Hong Kong) Limited, LFNY's Hong Kong office and an SFC licensed corporation.

Mr. Woo received his bachelor's degree in biology from Tufts University in the United States in May 1994, his master's degree in cellular, molecular and biomedical studies from the Columbia University Graduate School of Arts and Sciences in the United States in May 1998 and his master of business administration degree from the Columbia University Graduate School of Business in the United States in May 2003.

Neo Xiaofan Zhang

Chief Operating Officer

Mr. Zhang has been with CBC Group since January 2014, most recently serving as a managing director and responsible for the fund's investments in pharmaceutical and biotech industry prior to joining the company. Prior to joining CBC Group, Mr. Zhang worked in various capacities in private equity and investment banking, including as a private equity investment officer at Capital International, Inc., a private equity arm of Capital Group, from March 2011 to February 2013, at Morgan Stanley Asia Limited, a subsidiary of Morgan Stanley (NYSE: MS), from May 2007 to March 2011 where his last position held was associate, and at BOCI Research Limited and BOCI Securities Limited from 2006 to 2007.

Mr. Zhang received his bachelor's degree in mathematics with honors from The University of Hong Kong in December 2006.

Jason Brown, Ph.D.

Chief Business Officer

Prior to joining our Company from July 2007 to June 2016, Dr. Brown held multiple positions at Thomas, McNerney & Partners, a healthcare venture firm that invests in life science and medical technology companies, and his last position held was partner. From June 2003 to June 2007, Dr. Brown was employed by Forward Ventures, a life science venture capital firm located in San Diego, California, and his last position held was associate.

Dr. Brown received his bachelor's degree in biochemistry and molecular biology from Purdue University in the United States in May 1993 and his Ph.D. in biology from the University of California, San Diego in the United States in June 2000.

Yang Shi

Chief Medical Officer, Oncology

Before joining our Company, Ms. Shi was the head of China clinical development at Merck Serono (Beijing) Pharmaceutical Research and Development Co., Ltd. in China from February 2015 to February 2019. Ms. Shi was the oncology project development director in the medical department at Boehringer Ingelheim International Trading (Shanghai) Co., Ltd. in China and Germany from September 2010 to February 2015. Ms. Shi worked as a product physician, medical advisor and senior manager in oncology consecutively at Pfizer Investment Co., Ltd. in China, a subsidiary of Pfizer Inc. (NYSE: PFE), from September 2005 to September 2010.

Ms. Shi received her bachelor's degree in medicine from the Capital University of Medical Sciences, China in July 1998 and her master's degree in oncology from the Academy of Military Medical Sciences, China in July 2002.

Sunny Xu Zhu

Chief Medical Officer, Infectious Disease

Before joining our Company, Ms. Zhu served as a global clinical leader in the anti-infective therapeutic area of general medicine at Bayer Healthcare Company Limited from April 2013 to October 2017. Ms. Zhu held multiple positions at AstraZeneca Pharmaceutical Technology (Beijing) Co., Ltd., a subsidiary of AstraZeneca plc (LSE: AZN), in China and the United Kingdom from January 2003 to April 2013 and her last position held was executive director of drug development project and portfolio management. Ms. Zhu held multiple positions at MSD China from October 1995 to January 2003 and her last held position was clinical research manager.

Ms. Zhu received her bachelor's degree in preventive medicine from Beijing Medical University (now the Peking University Health Science Center) in July 1994 and her master's degree of medicine in public health and epidemiology and statistics from the Peking University Health Science Center in July 2009.

Zhengying Zhu, M.D., Ph.D.

Chief Medical Officer, Internal Medicine

Before joining our Company, Dr. Zhu served as chief medical officer and head of the business development at Luoxin Biological Technology (Shanghai) Co., Ltd. (now known as Luoxin Pharmaceuticals (Shanghai) Co., Ltd), a wholly-owned subsidiary of Shandong Luoxin Pharmaceutical Group Stock Co., Ltd. (HKEX: 8058, delisted), from October 2014 to October 2017. From November 2006 to October 2014, Dr. Zhu held multiple positions at Sino-American Shanghai Squibb Pharmaceuticals Limited, a subsidiary of Bristol-Myers Squibb (NYSE: BMY), and her last position held was senior medical director. Dr. Zhu worked as a physician at AstraZeneca Pharmaceutical Co., Ltd. in China from April 2005 to November 2006.

Dr. Zhu received her M.D. in clinical medicine in July 1996 and her Ph.D. in clinical medicine and internal medicine in July 2001, both from Shanghai Medical University (now known as Fudan University, School of Medicine). Dr. Zhu completed her post-doctoral fellowship training at the Division of Nephrology, University of Texas Southwestern Medical Center in Dallas, Texas, United States in December 2004.

Steven Xinhui Hu, Ph.D.

Chief Technology Officer

Dr. Hu served as the senior director and head of chemistry, manufacturing and controls in Roche R&D Center (China) Ltd. from July 2013 to October 2018, director of new product development in GlaxoSmithKline (China) Investment Co., Ltd., a subsidiary of GlaxoSmithKline plc (NYSE: GSK), from July 2010 to July 2013, and senior scientist research pharmacy in Merck & Co, Inc. (NYSE: MRK) from March 2008 to July 2010.

Dr. Hu received his Ph.D. in science mechanics from Brown University in the United States in May 2004 and was a postdoctoral associate in the Chemical Engineering Department at Massachusetts Institute of Technology in the United States from December 2003 to June 2005.

Kevin Yong Guo

Chief Commercial Officer

Mr. Guo has more than 22 years of commercial leadership and business management experience across a number of multinational pharmaceutical companies. Mr. Guo joins the Company after holding leadership positions at Eisai, where he most recently served as vice president and deputy global brand lead for LENVIMA, driving the development and execution of global product launch strategies, including in markets such as China, Japan and other Asia regions. Prior to this, he was vice president and head of the pharmaceutical business division of Eisai China Inc., where he managed several key business functions and was also appointed as chairman of the Board and president of Eisai (Suzhou) Trading Co., Ltd. In addition, Mr. Guo was the vice president of Oncology Business Unit 1 in Shanghai Roche Pharmaceutical Ltd., among other key commercial and business development positions at prominent global pharmaceutical companies, including GlaxoSmithKline plc, Wyeth Pharmaceutical Co., Ltd. (now part of Pfizer Inc.), Sino-American Shanghai Squibb Pharmaceutical Limited and Eli Lilly Asia Inc.. 

Mr. Guo obtained his Bachelor's degree in clinical medicine from Fourth Military University in China in 1994 and his Executive MBA from China Europe International Business School in 2011.

Jennifer Wei Yang, Ph.D

Chief Scientific Officer

Dr. Yang has two decades of leadership experience in drug discovery and development at global pharmaceutical companies.  Prior to joining Everest, Dr. Yang served as vice president and head of China for Johnson & Johnson’s Lung Cancer Initiative where she established and led a cross-sector research and development (R&D) organization for the creation of innovative solutions for lung cancer prevention, interception and cure. Jennifer transitioned into this role from Janssen (China) Research & Development Center, where she was the head of Discovery Center.  Prior to joining Johnson and Johnson, Dr. Yang held global leadership positions at Eli Lilly and Company and Pfizer Inc Oncology Research Unit in the United States.

Dr. Yang holds a Ph.D. in molecular biology and human genetics from the Eccles Institute of Human Genetics at the University of Utah, a Master’s degree in immunology and microbiology from Southern Illinois University, and a Bachelor of Science degree in microbiology from Fudan University in China.

 Copyright Everest Medicines 2020  云顶药业(苏州)有限公司 苏ICP备20038571号 |  Terms of Use |  Privacy Policy |  Disclaimers

沪公网安备 31010602006477号